16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway

Cancer Research

Volumn 65, Issue 17, 2005, Pages 7984-7992

  Lee, Sok Hyong ^a   Nishino, Michiya ^a   Mazumdar, Tuhina ^a   Garcia, Gabriela E ^a   Galfione, Matthew ^b   Lee, Florence L ^b   Lee, Cynthia L ^b   Liang, Albert ^b   Kim, Jeri ^b   Feng, Lili ^a   Eissa, N Tony ^a   Lin, Sue Hwa ^b   Yu Lee, Li Yuan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLACTIN; RNA; STAT1 PROTEIN;

ANGIOGENESIS; ANIMAL CELL; AORTA; ARTICLE; ENDOTHELIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDOTHELIAL CELLS; INTERFERON REGULATORY FACTOR-1; INTERLEUKIN-1; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROLACTIN; RATS; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 24744472074     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0631     Document Type: Article

References (61)

1. Lewis UJ, Singh RN, Sinha YN, et al. Glycosylated human PRL. Endocrinology 1985;116:353-63.
2. Oetting WS, Tuazon PT, Traugh JA, et al. Phosphorylation of PRL. J Biol Chem 1986;261:1649-52.
3. Mittra I. A novel "cleaved PRL" in the rat pituitary. I. Biosynthesis, characterization and regulatory control. Biochem Biophys Res Commun 1980;95:1750-9.
4. Sinha YN, Gilligan TA. A cleaved form of PRL in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors. Endocrinology 1984;114:2046-53.
5. Sinha YN, Gilligan TA, Lee DW, et al. Cleaved PRL: evidence for its occurrence in human pituitary gland and plasma. J Clin Endocrinol Metab 1985;60:239-43.
6. Sinha YN. Structural variants of PRL: occurrence and physiological significance. Endocr Rev 1995;16:354-69.
7. Baldocchi RA, Tan L, King DS, et al. Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat PRL: evidence that the cleaving enzyme is cathepsin D. Endocrinology 1993;133:935-8.
8. Piwnica D, Touraine P, Struman I, et al. Cathepsin D processes human PRL into multiple 16k-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 2004;18:2522-42.
9. Clapp C. Analysis of the proteolytic cleavage of PRL by the mammary gland and liver of the rat. Characterization of the cleaved and 16k forms. Endocrinology 1987;121:2055-64.
10. Clapp C, Torner L, Gutierrez-Ospina G, et al. The PRL gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa PRL. Proc Natl Acad Sci 1994;91:10384-8.
11. Clapp C, Martial JA, Guzman RC, et al. The 16-kilodalton N-terminal fragment of human PRL is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-9.
12. Struman I, Bentzien F, Lee H, et al. Opposing actions of intact and N-terminal fragments of the human PRL/growth hormone family members on angiogenesis: an efficient mechanism of the regulation of angiogenesis. Proc Natl Acad Sci 1999;96:1246-51.
13. Bentzien F, Struman I, Martini J, et al. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1-/-mice. Cancer Res 2001;61:7356-62.
14. Duenas Z, Torner L, Corbacho AM, et al. Inhibition of rat corneal angiogenesis by 16-kDa PRL and by endogenous PRL-like molecules. Invest Ophthalmol Vis Sci 1999;40:2498-505.
15. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
16. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 1994;79:315-28.
17. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;79:315-28.
18. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
19. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-6.
20. Kim J, Luo W, Chen D-T, et al. Antitumor activity of the 16-kDa PRL fragment in prostate cancer. Cancer Res 2003;63:386-93.
21. Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1b promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002;169:469-75.
22. Song X, Voronov E, Dvorkin T, et al. Differential effects of IL-1a and IL-1b on tumorigenicity patterns and invasiveness. J Immunol 2003;171:6448-56.
23. Bar D, Apte RN, Voronov E, et al. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 2004;18:161-3.
24. Ziche M, Parenti A, Ledda F, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997;80:845-52.
25. Murohara T, Witzenbichler B, Spyridopoulos I, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999;19:1156-61.
26. Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost 2003;1:2112-8.
27. Teng X, Zhang H, Snead C, et al. Molecular mechanisms of iNOS induction by IL-1b and IFN-g in rat aortic smooth muscle cells. Am J Physiol Cell Physiol 2002;282:C144-52.
28. Saura M, Zaragoza C, Bao C, et al. Interaction of interferon regulatory factor-1 and nuclear factor κB during activation of inducible nitric oxide synthase transcription. J Mol Biol 1999;289:459-71.
29. Taylor BS, Geller DA, Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 2000;13:413-24.
30. Galfione M, Luo W, Kim J, et al. Expression and purification of the antiangiogenesis inhibitor 16-kDa PRL fragment from insect cells. Protein Expr Purif 2003;28:252-9.
31. 1-S transition in the PRL-induced lymphocyte cell cycle. Mol Endocrinol 1992;6:2236-43.
32. Diglio CA, Grammas P, Giacomelli F, et al. Angiogenesis in rat aorta ring explant cultures. Lab Invest 1988;60:523-31.
33. Garcia GE, Xia Y, Chen S, et al. NF-κB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1β, TNF-α, and LPS. J Leukoc Biol 2000;67:577-84.
34. 15N] nitrate in biological fluids. Anal Biochem 1982;126:131-8.
35. Guo FH, Comhair SA, Zheng S, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol 2000;164:5970-80.
36. Wang Y, O'Neal KD, Yu-Lee Ly. Multiple PRL receptor cytoplasmic residues and Stat1 mediate PRL signaling to the IRF-1 promoter. Mol Endocrinol 1997;11:1353-64.
37. McAlexander MB, Yu-Lee Ly. Sp1 is required for PRL activation of the interferon regulatory factor 1 gene. Mol Cell Endocrinol 2001;184:135-41.
38. Fujita T, Reis LF, Watanabe N, et al. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci 1989;86:9936-40.
39. Stevens AM, Wang Y, Sieger KA, et al. Biphasic transcriptional regulation of the interferon regulatory factor-1 gene by PRL: involvement of γ-interferon activated sequence and Stat-related proteins. Mol Endocrinol 1995;9:513-25.
40. Wang Y, Yu-Lee Ly. Multiple Stat complexes interact at the IRF-1 GAS in PRL-stimulated Nb2 T cells. Mol Cell Endocrinol 1996;121:19-28.
41. Decker T, Kovarik P. Serine phosphorylation of Stats. Oncogene 2000;19:2628-37.
42. Strehlow I, Schindler C. Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation. J Biol Chem 1998;273:28049-56.
43. Taniguchi T, Ogasawara K, Takaoka A, et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001;19:623-55.
44. Yu-Lee Ly. PRL modulation of immune and inflammatory responses. Recent Prog Horm Res 2002;57:435-55.
45. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
46. Nguyen H, Chatterjee-Kishore M, Jiang Z, et al. IRAK-dependent phosphorylation of Stat1 on serine 727 in response to interleukin-1 and effects on gene expression. J Interferon Cytokine Res 2003;23:183-92.
47. Varinou L, Ramsauer K, Karaghiosoff M, et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFNg-dependent innate immunity. Immunity 2003;19:793-802.
48. McAlexander MB, Yu-Lee Ly. PRL activation of IRF-1 transcription involves changes in histone acetylation. FEBS Lett 2001;488:91-4.
49. Abdollahi A, Hahnfeldt P, Grone H-J, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
50. Macotela Y, Mendoza C, Corbacho AM, et al. 16k PRL induces NFκB activation in pulmonary fibroblasts. J Endocrinol 2002;175:R13-8.
51. Tabruyn SP, Sorlet CM, Rentier-Delrue F, et al. The antiangiogenic factor 16K human PRL induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-κB. Mol Endocrinol 2003;17:1815-23.
52. D'Angelo G, Martini J, Iiri T, et al. 16K human PRL inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999;13:692-704.
53. Koshida R, Ou J, Matsunaga T, et al. Angiostatin: a negative regulator of endothelial-dependent vasodilation. Circulation 2002;107:803-6.
54. Urbich C, Reissner A, Chavakis E, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the antiangiogenic effects of endostatin. FASEB J 2002;16:706-8.
55. Gonzalez C, Corbacho AM, Eiserich JP, et al. 16K PRL inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization and endothelium-dependent vase-relaxation. Endocrinology 2004;145:5714-22.
56. Corbacho AM, Nava G, Eiserich J, et al. Proteolytic cleavage confers nitric oxide synthase inducing activity upon PRL. J Biol Chem 2000;275:13183-6.
57. Clapp C, Weiner RI. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of PRL on capillary endothelial cells. Endocrinology 1992;130:1380-6.
58. Martini J, Piot C, Humeau LM, et al. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 2000;14:1536-49.
59. 2-M phases. Mol Endocrinol 2005;19:1932-42.
60. Duenas Z, Rivera JC, Quiroz-Mercado H, et al. PRL in eyes of patients with retinopathy of prematurity: implications with vascular regression. Invest Ophthalmol Vis Sci 2004;45:2049-55.
61. Pan H, Nguyen N-QN, Yoshida H, et al. Molecular targeting of antiangiogenic factor 16k hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 2004;45:2413-9.